INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 212 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.87 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $6,657,000 | +876.1% | 59,511 | +1346.5% | 0.05% | +683.3% |
Q3 2015 | $682,000 | -93.6% | 4,114 | -90.6% | 0.01% | -92.1% |
Q2 2015 | $10,619,000 | +46.3% | 43,993 | +71.0% | 0.08% | +46.2% |
Q1 2015 | $7,256,000 | +51.7% | 25,728 | -16.1% | 0.05% | +48.6% |
Q4 2014 | $4,782,000 | – | 30,653 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |